Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Annals of the New York Academy of Sciences|January 26, 1999
Interleukin-11. A gp130 cytokineWilliam L Trepicchio, Andrew J DornerJournal of Immunology Research|June 25, 2016
Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical RelevanceSam Song, Lili Yang, William L Trepicchio, et al.Journal of Immunological Methods|October 5, 2010
Validation of a flow cytometry based G(2)M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibitionJose Estevam, Hadi Danaee, Ray Liu, et al.Experimental Biology and Medicine (Maywood, N.J.)|April 21, 2004
Interleukin-11 inhibits NF-kappaB and AP-1 activation in islets and prevents diabetes induced with streptozotocin in miceAbdelhakim Lgssiar, Mohamed Hassan, Patricia Schott-Ohly, et al.Plos One|December 21, 2017
Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancersHadi Danaee, Thea Kalebic, Timothy Wyant, et al.Archives of Dermatology|February 18, 2003
Narrowband (312-nm) UV-B suppresses interferon gamma and interleukin (IL) 12 and increases IL-4 transcripts: differential regulation of cytokines at the single-cell levelIan B Walters, Maki Ozawa, Irma Cardinale, et al.The Journal of Experimental Medicine|January 7, 2004
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgarisEdmund Lee, William L Trepicchio, Judith L Oestreicher, et al.Current Molecular Medicine|February 22, 2005
Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trialsMichael E Burczynski, Judith L Oestreicher, Monica J Cahilly, et al.JMIR Research Protocols|March 22, 2017
Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate FeasibilityBin Li, Steven A Eschrich, Anders Berglund, et al.Plos One|June 25, 2015
Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or SorafenibBin Li, Hyunjin Shin, Georgy Gulbekyan, et al.Pageof 3